改良法国门诊剖宫产术与标准剖宫产技术的比较——一项随机双盲对照试验
这项双盲随机对照试验纳入116名足月择期剖宫产妇女,比较改良法国门诊剖宫产术与标准剖宫产技术。两组主要不良复合结局无显著差异(38.9% vs 53.8%,P=.172),但改良组手术时间更长、术中并发症及脐带血pH<7.2比例更高。作者认为两组产妇恢复均良好,围术期管理是影响恢复的主要因素。
要点
- 两组主要不良复合结局无显著差异(38.9% vs 53.8%,P=.172)。
- 改良组手术时间更长、术中并发症及脐带血pH<7.2比例更高。
- 术后1周电话评估改良组恢复质量评分优于标准组。
核心结论
- 两组产妇恢复均良好,作者认为影响恢复的主要因素是围术期管理(包括避免术中使用静脉补液、鞘内吗啡和膀胱导管,以及术后早期活动)。
- 法国门诊剖宫产技术的产妇和新生儿安全性结局尚需更大规模高质量随机对照试验证实。
研究设计与样本
- 双盲随机对照试验,纳入足月择期剖宫产妇女,随机分配至改良法国门诊剖宫产术组与标准剖宫产技术组,每组58例,共116例。
- 改良法国门诊剖宫产术遵循法国门诊剖宫产术所有手术步骤,但不采用腹膜外入路。
- 两组均避免使用静脉补液、鞘内吗啡和膀胱导管,所有产妇均鼓励术后3至4小时站立和行走。
- 主要不良复合结局包括:术后3至4小时视觉模拟评分>6分、术后3至4小时无法站立并行走至洗手间、术后24小时15项恢复质量问卷评分<90分。
- 随访6周。
主要发现
- 主要不良复合结局两组无显著差异:法国门诊剖宫产组38.9% vs 标准剖宫产组53.8%(P=.172)。
- 两组均有超过90%的产妇术后3至4小时能够起身行走。
- 与标准剖宫产组相比,法国门诊剖宫产组手术时间更长(43.7±11.2 vs 54.4±11.3分钟;P<.001)。
- 与标准剖宫产组相比,法国门诊剖宫产组术中并发症发生率更高(0.0% vs 13.8%;P=.006),脐带血pH<7.2发生率更高(3.4% vs 17.2%;P=.029)。
- 术后1周电话评估显示法国门诊剖宫产组恢复质量评分优于标准剖宫产组(27.1±8.4 vs 24.6±8.0;P=.043)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 法国门诊剖宫产技术的产妇和新生儿安全性结局尚需更大规模高质量随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The French AmbUlatory Cesarean Section is a cesarean delivery technique, which includes a vertical fascial incision to the left of the linea alba and an extraperitoneal approach to the uterus. The presumed benefits of this technique are decreased postoperative pain and accelerated recovery. However, evidence supporting these impressions is scarce. OBJECTIVE: This study aimed to compare maternal recovery after French AmbUlatory Cesarean Section vs standard cesarean delivery technique. STUDY DESIGN: In this double-blind randomized controlled trial, women undergoing elective cesarean delivery at term were allocated into French AmbUlatory Cesarean Section vs standard cesarean delivery technique. A modified French AmbUlatory Cesarean Section technique was used, adhering to all French AmbUlatory Cesarean Section operative steps except for the extraperitoneal approach. In both groups, the use of intravenous hydration, intrathecal morphine, and bladder catheter was avoided, and all women were encouraged to stand and walk 3 to 4 hours after the operation. The primary adverse composite outcome included either of the following: a visual analog scale score of >6 at 3 to 4 hours after the operation, an inability to stand up and walk to the restroom 3 to 4 hours after the operation, and a 15-Item Quality of Recovery (QoR) questionnaire score of <90 at 24 hours after the operation. The women were followed up for 6 weeks. RESULTS: Overall, 116 women were included in the trial (58 in each group). The adverse composite outcome did not differ between the 2 groups (38.9% for the French AmbUlatory Cesarean Section group vs 53.8% for the regular cesarean delivery group; P=.172). In both groups, more than 90% of the women were able to get up and walk 3 to 4 hours after the operation. Compared with the standard cesarean delivery group, the French AmbUlatory Cesarean Section group had a longer duration of the operation (43.7±11.2 vs 54.4±11.3 minutes; P<.001), a higher rate of intraoperative complications (0.0% vs 13.8%; P=.006), and a higher rate of umbilical cord pH level of <7.2 (3.4% vs 17.2%; P=.029) were noted. Evaluation via phone call 1 week after the operation showed better quality of recovery scores in the French AmbUlatory Cesarean Section group than in the standard cesarean delivery group (27.1±8.4 vs 24.6±8.0; P=.043). Other secondary outcomes did not differ between the 2 groups. CONCLUSION: As excellent maternal recovery was noted in both groups, we believe that the main factor affecting this recovery is the perioperative management (including avoidance of the use of intraoperative intravenous hydration, intrathecal morphine, and bladder catheter, with early postoperative mobilization). The maternal and neonatal safety outcomes of the French AmbUlatory Cesarean Section technique remain to be proven by larger-scale high-quality randomized controlled trials.
引用
- Sagi S, Bleicher I, Bakhous R, et al. Comparison between the modified French AmbUlatory Cesarean Section and standard cesarean technique-a randomized double-blind controlled trial. Am J Obstet Gynecol MFM. 2023. PMID: 36828283. doi:10.1016/j.ajogmf.2023.100910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。